Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Ionis Pharmas rare...

    Ionis Pharmas rare metabolic disorder drug succeeds key study

    Written by supriya kashyap kashyap Published On 2016-12-23T12:30:48+05:30  |  Updated On 23 Dec 2016 12:30 PM IST
    Ionis Pharmas rare metabolic disorder drug succeeds key study

    Ionis Pharmaceuticals Inc said its rare metabolic disorder drug for severe hypertriglyceridemia, characterized by elevated levels of a type of fat in the blood, met the main goal in a late stage study.


    The drug, volanesorsen, brought about a statistically significant 71.2 percent mean reduction in triglycerides after 13 weeks of treatment, compared with 0.9 percent in those who got the placebo, the company said.


    However, Ionis said that a patient who was on the drug experienced a serious side-effect. The episode of serum sickness occurred two weeks after the last study dose and was resolved by itself. The case was unlikely caused by volanesorsen, the company added.


    Patients in the trial had two rare metabolic disorders: familial chylomicronemia syndrome and familial partial lipodystrophy.


    Familial chylomicronemia syndrome is a rare genetic disorder characterized by extremely high levels of triglycerides and the risk of recurrent, potentially fatal pancreatitis.


    Familial partial lipodystrophy is a rare, underdiagnosed metabolic disorder characterized by an inability of the body to store fat in normal locations.


    The data from the study will form part of the marketing applications for volanesorsen in the United States, Canada and Europe next year, CEO Paula Soteropoulos said.


    There are three other late-stage studies currently testing the drug, the company said.


    Ionis's stock was up 1.4 percent at $50 in premarket trading. Up to Friday's close, the company's stock had fallen about 20 percent this year.

    HypertriglyceridemiaIonisIonis Pharmametabolic disorder drugPaula Soteropoulos
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok